BioXcel Therapeutics マネジメント
マネジメント 基準チェック /24
BioXcel Therapeutics' CEO is Vimal Mehta, appointed in May 2017, has a tenure of 7.5 years. total yearly compensation is $4.73M, comprised of 21.2% salary and 78.8% bonuses, including company stock and options. directly owns 0.13% of the company’s shares, worth $34.51K. The average tenure of the management team and the board of directors is 7.1 years and 6.3 years respectively.
主要情報
Vimal Mehta
最高経営責任者
US$4.7m
報酬総額
| CEO給与比率 | 21.2% |
| CEO在任期間 | 7.5yrs |
| CEOの所有権 | 0.1% |
| 経営陣の平均在職期間 | 7.1yrs |
| 取締役会の平均在任期間 | 6.3yrs |
経営陣の近況
CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$108m |
| Mar 31 2024 | n/a | n/a | -US$153m |
| Dec 31 2023 | US$5m | US$1m | -US$179m |
| Sep 30 2023 | n/a | n/a | -US$212m |
| Jun 30 2023 | n/a | n/a | -US$203m |
| Mar 31 2023 | n/a | n/a | -US$187m |
| Dec 31 2022 | US$5m | US$944k | -US$166m |
| Sep 30 2022 | n/a | n/a | -US$137m |
| Jun 30 2022 | n/a | n/a | -US$122m |
| Mar 31 2022 | n/a | n/a | -US$112m |
| Dec 31 2021 | US$9m | US$917k | -US$107m |
| Sep 30 2021 | n/a | n/a | -US$102m |
| Jun 30 2021 | n/a | n/a | -US$100m |
| Mar 31 2021 | n/a | n/a | -US$94m |
| Dec 31 2020 | US$10m | US$890k | -US$82m |
| Sep 30 2020 | n/a | n/a | -US$69m |
| Jun 30 2020 | n/a | n/a | -US$54m |
| Mar 31 2020 | n/a | n/a | -US$41m |
| Dec 31 2019 | US$2m | US$459k | -US$33m |
| Sep 30 2019 | n/a | n/a | -US$32m |
| Jun 30 2019 | n/a | n/a | -US$28m |
| Mar 31 2019 | n/a | n/a | -US$22m |
| Dec 31 2018 | US$702k | US$423k | -US$19m |
| Sep 30 2018 | n/a | n/a | -US$15m |
| Jun 30 2018 | n/a | n/a | -US$11m |
| Mar 31 2018 | n/a | n/a | -US$8m |
| Dec 31 2017 | US$284k | US$147k | -US$5m |
報酬と市場: Vimal's total compensation ($USD4.73M) is above average for companies of similar size in the US market ($USD655.02K).
報酬と収益: Vimal's compensation has increased whilst the company is unprofitable.
CEO（最高経営責任者
Vimal Mehta (63 yo)
7.5yrs
在職期間
US$4,731,147
報酬
Dr. Vimal D. Mehta, Ph D., is Co-Founder of BioXcel Corporation and following its inception in 2005, has served as its Chairman and Chief Executive Officer. Dr. Mehta served as a Director at Invea Therapeu...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 7.5yrs | US$4.73m | 0.13% $ 34.5k | |
| Senior VP | 3.8yrs | US$1.12m | 0.058% $ 15.3k | |
| Senior VP & CFO | 7.1yrs | US$404.00k | 0.050% $ 13.0k | |
| Senior VP & Chief Scientific Officer | 7.4yrs | US$1.15m | 0.069% $ 18.2k | |
| Executive VP and Chief of Product Development & Medical Officer | 7.3yrs | US$510.17k | 0.048% $ 12.6k | |
| Senior VP and Head of Translational Medicine | 2.3yrs | データなし | データなし | |
| Chief Medical Officer - Neuroscience | 2.8yrs | データなし | データなし |
7.1yrs
平均在職期間
63yo
平均年齢
経験豊富な経営陣: BTAI's management team is seasoned and experienced (7.1 years average tenure).
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Founder | 7.6yrs | US$4.73m | 0.13% $ 34.5k | |
| Member of Advisory Board | no data | データなし | データなし | |
| Independent Chairman & Lead Director | 7.6yrs | US$367.33k | 0.57% $ 149.6k | |
| Member of Clinical Advisory Board | 6.3yrs | データなし | データなし | |
| Member of Clinical Advisory Board | 5.8yrs | データなし | データなし | |
| Member of Clinical Advisory Board | 5.8yrs | データなし | データなし | |
| Member of Clinical Advisory Board | 6.3yrs | データなし | データなし | |
| Member of Clinical Advisory Board | 6.3yrs | データなし | データなし | |
| Member of Clinical Advisory Board | 5.8yrs | データなし | データなし | |
| Independent Director | 7.2yrs | US$329.83k | 0% $ 0 | |
| Member of Advisory Board | no data | データなし | データなし | |
| Member of Clinical Advisory Board | 6.3yrs | データなし | データなし |
6.3yrs
平均在職期間
63yo
平均年齢
経験豊富なボード: BTAI's board of directors are considered experienced (6.3 years average tenure).